

In the Claims

Please amend the claims as follows:

1. (Currently Amended) A mechanically stable biphasic injectable soft tissue augmentation composition comprising:

biocompatible micronized textured polyethylene particles having a size greater than sixty microns, and

a physiological carrier, wherein the composition is injected into soft tissue.

2. (Canceled)

3. (Canceled)

4. (Previously Presented) The composition of Claim 1, wherein the physiological carrier is selected from polyvinylpyrrolidone, silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.

5. (Canceled)

6. (Canceled)

7. (Previously Presented) The composition of Claim 1, wherein the physiological carrier is polyvinylpyrrolidone.

8. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

9. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

10. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

11. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value of 17.

12. (Canceled)

13. (Previously Presented) The composition of Claim 1 wherein the biocompatible micronized textured polyethylene and the physiological carrier are combined at a ratio of approximately 3:2 physiological carrier to biocompatible micronized textured polyethylene by weight.

14. (Canceled)

15. (Currently Amended) A method for soft tissue augmentation comprising:
injecting into soft tissue a mechanically stable biphasic injectable composition comprising:
biocompatible micronized textured polyethylene particles having a size greater than sixty microns, and
a physiological carrier.

16. (Cancelled)

17. (Previously Presented) The method of Claim 15, wherein the physiological carrier is selected from polyvinylpyrrolidone, silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, water or autologous plasma.

18. (Currently Amended) The method of Claim 15, wherein injecting comprises:
inserting a delivery apparatus containing the mechanically stable biphasic injectable composition into the injection site.

19. (Previously Presented) The method of Claim 15, wherein the injecting comprises subcutaneous, intradermal, intramuscular, periurethral injection or injecting the vocal cords.

20. (Previously Presented) The composition of Claim 1, wherein the biocompatible micronized textured polyethylene particles have a size greater than eighty microns.

21. (Previously Presented) The composition of Claim 1, wherein the biocompatible micronized textured polyethylene particles have a size greater than one-hundred microns.

22. (Currently Amended) A mechanically stable biphasic injectable soft tissue augmentation composition comprising:

biocompatible micronized textured polyethylene particles having a size of greater than sixty microns; and

a physiological carrier comprising polyvinylpyrrolidone, wherein the composition is injected into soft tissue.

23. (Previously Presented) The composition of Claim 22 wherein the biocompatible micronized textured polyethylene and the physiological carrier are combined at a ratio of approximately 3:2 physiological carrier to biocompatible micronized textured polyethylene by weight.

24. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.

25. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

26. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.

27. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value of 17.

28. (Previously Presented) The composition of Claim 22, wherein the biocompatible micronized textured polyethylene particles have a size greater than eighty microns.

29. (Previously Presented) The composition of Claim 22, wherein the biocompatible micronized textured polyethylene particles have a size greater than one-hundred microns.